# Superfluid Dx, Inc.

> Superfluid Dx is a South San Francisco diagnostics company building a blood-based test for Alzheimer's disease and other neurodegenerative conditions. Its platform isolates cell-free messenger RNA (cf-mRNA) from a single tube of blood and pairs next-generation sequencing with RNA deconvolution and machine-learning analysis to read out organ-level biology - aiming to detect disease years earlier than conventional methods and to guide therapy. The company was formed in late 2023 when WRQ Sciences acquired and renamed Molecular Stethoscope, and is led by Fluidigm co-founder Gajus Worthington alongside Stanford bioengineer and serial founder Steve Quake.

- **Founded:** 2023
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Gajus Worthington (Chairperson & CEO; Co-Founder of WRQ Sciences (Fluidigm co-founder)), Kartik Raghavan (Co-Founder & Managing Partner, WRQ Sciences; Board Member), Steve Quake (Co-Founder & Board Member; Stanford bioengineer, ex-Chan Zuckerberg Biohub)
- **Team size:** ~8 employees
- **Products:** cf-mRNA liquid biopsy platform, Blood-based Alzheimer's / neurodegenerative test, Therapy-guidance & disease-monitoring analytics
- **Notable:** Closed an oversubscribed Series A in December 2023 led by WRQ Sciences., Reborn from Molecular Stethoscope (founded 2014) on research from Steve Quake's Stanford lab and Scripps Research., Backed by the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.

## Products & services

- **cf-mRNA liquid biopsy platform** — Isolates cell-free messenger RNA from a routine blood draw and combines next-generation sequencing with RNA deconvolution algorithms and bioinformatics to yield organ-level insights into health and disease.
- **Blood-based Alzheimer's / neurodegenerative test** — A minimally invasive test in development that measures RNA released from brain cells plus indirect pathological signals in circulating cells, aiming for earlier and more precise diagnosis than amyloid/tau or APOE-based assays.
- **Therapy-guidance & disease-monitoring analytics** — Pathway-enrichment and machine-learning analysis intended to help match patients to therapies, avoid drugs with severe side effects, and monitor disease over time; positioned for clinical-trial diagnostics as well.

## Achievements

- Closed an oversubscribed Series A in December 2023 led by WRQ Sciences.
- Reborn from Molecular Stethoscope (founded 2014) on research from Steve Quake's Stanford lab and Scripps Research.
- Backed by the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.
- Published peer-reviewed work showing CSF cf-mRNA transcripts can discriminate Alzheimer's from non-cognitively-impaired subjects (Alzheimer's & Dementia: TRCI, 2025).

## Latest updates

- **2025-09** — Peer-reviewed study in Alzheimer's & Dementia: Translational Research & Clinical Interventions reports CSF cf-mRNA reveals molecular dysregulations that distinguish Alzheimer's patients.
- **2023-12** — WRQ Sciences and Superfluid Dx announce completion of an oversubscribed Series A; Molecular Stethoscope renamed Superfluid Dx, Inc.

## Links

- Website: https://superfluiddx.com
- LinkedIn: http://www.linkedin.com/company/superfluid-dx-inc

---

Profile page: https://yespress.io/superfluid-dx-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-11